Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. DCIS is particularly clinically challenging, due to its heterogeneous pathological and biological traits and its management is continually evolving towards more personalized and less aggressive therapies. This article suggests evidence-based guidelines for proper DCIS clinical management, which should be discussed within a multidisciplinary team in order to propose the most suitable approach in clinical practice, taking into account recent scientific studies.Here we include updated multidisciplinary treatment protocols and techniques in accordance with the most recent contributions published on this topic in the peer-reviewed medical literature, and we outline future perspectives. (C) 2021 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Advances and controversies in management of breast ductal carcinoma in situ (DCIS) / G. Farante, A. Toesca, F. Magnoni, G. Lissidini, J. Vila, M. Mastropasqua, G. Viale, S. Penco, E. Cassano, M. Lazzeroni, B. Bonanni, M.C. Leonardi, F. Ripoll-Orts, G. Curigliano, R. Orecchia, V. Galimberti, P. Veronesi. - In: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. - ISSN 0748-7983. - 48:4(2022 Apr), pp. 736-741. [10.1016/j.ejso.2021.10.030]

Advances and controversies in management of breast ductal carcinoma in situ (DCIS)

G. Viale;G. Curigliano;P. Veronesi
Ultimo
2022

Abstract

Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. DCIS is particularly clinically challenging, due to its heterogeneous pathological and biological traits and its management is continually evolving towards more personalized and less aggressive therapies. This article suggests evidence-based guidelines for proper DCIS clinical management, which should be discussed within a multidisciplinary team in order to propose the most suitable approach in clinical practice, taking into account recent scientific studies.Here we include updated multidisciplinary treatment protocols and techniques in accordance with the most recent contributions published on this topic in the peer-reviewed medical literature, and we outline future perspectives. (C) 2021 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Breast cancer; Ductal carcinoma in situ; Guidelines; Medical treatment; Radiotherapy; Surgery; Female; Humans; Survival Rate; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating
Settore MED/08 - Anatomia Patologica
Settore MED/18 - Chirurgia Generale
Settore MED/06 - Oncologia Medica
9-nov-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
DCIS Farante.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 355.29 kB
Formato Adobe PDF
355.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/936151
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact